Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff P, Higano C, Shore N, Berger E, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff P, Higano C, Shore N, Berger E, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Breast cancer incidence rates in women decreased 3.5% per year from 2001-2004, the first decrease observed in 20 years.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.  
  • When detected early, the 5-year survival rate for colorectal cancer is 90%; however, only 39% of colorectal cancers are diagnosed early, mainly because of low rates of screening.  
  • Cervical cancer screening reduces incidence by over 80%.  
  • Decline in Cancer Death Rates in Men